Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes
Authors:
Open Access
- 1 December 2015
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (12) , 2185-2191
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81230013)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z121107002812033, Z121107002612035)
- National Natural Science Foundation of China (81370666)
- National Natural Science Foundation of China (81400145)
This publication has 30 references indexed in Scilit:
- Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantationHaematologica, 2013
- Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationClinical Infectious Diseases, 2013
- Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk PatientsTransplantation and Cellular Therapy, 2011
- Risk factors for post‐transplant lymphoproliferative disorder in pediatric patients: A case‐control studyPediatric Transplantation, 2005
- Post-Transplant Lymphoproliferative DisordersAnnual Review of Medicine, 2005
- New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk FactorsJournal of Clinical Oncology, 2003
- Post-transplant lymphoproliferative disorder: a reviewBone Marrow Transplantation, 2003
- The management of lymphoma in the immunosuppressed patientBest Practice & Research Clinical Haematology, 2002
- Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantationBlood, 2002
- Pretransplantation Assessment of the Risk of Lymphoproliferative DisorderClinical Infectious Diseases, 1995